RxDoctor Payments Data

Sandy McGaffigan, MD

Neurology · Austell, GANPI 1164460614

Payments from drug & device makers

$13,023in general payments, 2019–2025

Across 628 payments — averaging $20.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • UCB, Inc.$1K
  • Biogen$957
  • AbbVie$797
  • AstraZeneca$769
  • Acadia Pharmaceuticals Inc$561
  • Novartis$501
  • plus $8K from 54 others

What the payments were for

  • Food & beverage$12,86199%
  • Education$1631%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
UCB, Inc.55$1,400
Biogen52$957
AbbVie(2 entities)66$797
AstraZeneca(2 entities)32$769
Acadia Pharmaceuticals Inc30$561
Novartis28$501
Teva Pharmaceuticals USA, Inc.21$411
Lundbeck LLC15$405
Sumitomo Pharma America, Inc.16$376
Sunovion Pharmaceuticals Inc.18$370
Jazz Pharmaceuticals Inc.10$356
MDD US Operations, LLC14$338
Lilly USA, LLC18$334
Argenx US, Inc.14$334
Grifols USA, LLC14$297
Johnson & Johnson(2 entities)14$291
Harmony Biosciences LLC10$276
Amgen14$256
Upsher-smith Laboratories LLC12$238
Otsuka America Pharmaceutical, Inc.9$231
Pfizer13$230
Eisai Inc.10$219
Biohaven Pharmaceuticals, Inc.8$218
Greenwich Biosciences, Inc.8$212
Neurelis, Inc.7$176
CSL Behring7$169
ANI Pharmaceuticals, Inc.7$168
Kyowa Kirin, Inc.9$153
Mallinckrodt Hospital Products Inc.6$152
Neurocrine Biosciences, Inc.7$143
Amneal Pharmaceuticals LLC9$133
Sanofi5$132
Genentech USA, Inc.5$113
SK Life Science, Inc.5$109
W. L. Gore & Associates, Inc.4$106
GE HealthCare4$101
Arbor Pharmaceuticals, Inc.7$99
Biohaven Pharmaceutical Holding Company Ltd.5$95
Aucta Pharmaceuticals, Inc.6$88
TG Therapeutics, Inc.2$69
Axsome Therapeutics, Inc.2$68
Takeda Pharmaceuticals U.S.A., Inc.3$66
Adamas Pharmaceuticals, Inc.3$54
Corium, LLC3$50
Avanir Pharmaceuticals, Inc.2$41
Impel Pharmaceuticals LLC3$38
Acorda Therapeutics, Inc2$38
Vanda Pharmaceuticals Inc.1$31
Springworks Therapeutics, Inc.1$30
Mallinckrodt Enterprises LLC1$26
Banner Life Sciences, LLC1$23
Tanabe Pharma America, Inc.1$22
Impel Pharmaceuticals Inc.1$22
Sanofi-aventis U.S. LLC1$22
Genentech, Inc.1$20
EMD Serono, Inc.1$17
Ipsen Biopharmaceuticals, Inc1$16
Idorsia Pharmaceuticals US Inc1$15
Zyla Life Sciences, Inc.1$14
Boston Scientific1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,023 in reported general payments places this provider in the 75th percentile of 506 neurology providers in Georgia.

See all neurology providers in Georgia

Medicare billing

Part B allowed, 2024
$85,883
Medicare patients
297
Services billed
634

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Vyvgart HytruloEfgartigimod-Hyaluronidas-Qvfc12$194,345
Nurtec OdtRimegepant Sulfate39$57,314
UbrelvyUbrogepant41$48,422
RexultiBrexpiprazole17$37,837
Aimovig AutoinjectorErenumab-Aooe39$37,143
KeppraLevetiracetam13$31,800
QuliptaAtogepant16$19,133
VimpatLacosamide11$13,649
Emgality PenGalcanezumab-Gnlm11$13,141
Memantine Hcl388$9,199
BrilintaTicagrelor11$8,320
Memantine Hcl ErMemantine Hcl71$5,744
DepakoteDivalproex Sodium12$5,715
Levetiracetam138$5,686
Lacosamide58$4,621

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Argenx US, Inc.Vyvgart Hytrulo$334$194,34512 claims
AbbVieUbrelvy, Qulipta$797$67,55557 claims
PfizerNurtec Odt$230$57,31439 claims
Otsuka America Pharmaceutical, Inc.Rexulti$231$37,83717 claims
UCB, Inc.Vimpat$1,400$13,64911 claims
AstraZenecaBrilinta$769$8,32011 claims
Upsher-smith Laboratories LLCTopiramate$238$1,43088 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 506 neurology providers in Georgia.

Other neurology in Austell

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →